Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2026)

Rigel Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $29.9 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 101.59% year-over-year to $29.9 million in Q1 2026; TTM through Mar 2026 was $29.9 million, a 101.59% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, up 309.96% from the prior year.
• Short term Debt steadied at $29.9 million in Q1 2026 per RIGL's latest filing, from $29.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $29.9 million in Q1 2026 and bottomed at $7.2 million in Q4 2023.
• The 4-year median for Short term Debt is $18.6 million (2025), against an average of $19.5 million.
• Biggest YoY gain for Short term Debt was 309.96% in 2025; the steepest drop was 0.24% in 2025.
• Year by year, Short term Debt stood at $7.2 million in 2023, then climbed by 0.59% to $7.3 million in 2024, then jumped by 309.96% to $29.8 million in 2025, then climbed by 0.18% to $29.9 million in 2026.
• Per Business Quant, the three latest RIGL Short term Debt figures stand at $29.9 million (Q1 2026), $29.8 million (Q4 2025), and $29.8 million (Q3 2025).